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MB-003, a plant-derived monoclonal antibody cock-
tail used effectively in treatment of Ebola virus infec-
tion in non-human primates, was unable to protect
two of six animals when initiated 1 or 2 days post-
infection. We characterized a mechanism of viral
escape in one of the animals, after observation of
two clusters of genomic mutations that resulted in
five nonsynonymous mutations in the monoclonal
antibody target sites. These mutations were linked
to a reduction in antibody binding and later
confirmed to be present in a viral isolate that was
not neutralized in vitro. Retrospective evaluation of
a second independent study allowed the identifica-
tion of a similar case. Four SNPs in previously identi-
fied positions were found in this second fatality,
suggesting that genetic drift could be a potential
cause for treatment failure. These findings highlight
the importance selecting different target domains
for each component of the cocktail to minimize the
potential for viral escape.
INTRODUCTION
Ebolaviruses (Bundibugyo, Ebola, Reston, Sudan, and Taı¨ Forest
viruses) are endemic to Africa and Southeast Asia and cause se-
vere febrile bleeding disorders leading to multi-organ failure in
humans and/or nonhuman primates (NHPs) (Kuhn, 2008). The
mean lethality of ebolavirus infections is extremely high (mean
as of March 11, 2015: 41%) (WHO, 2015). Prior to the current
sustained epidemic in Western Africa (Baize et al., 2014), caused
by Ebola virus (EBOV), outbreaks have typically occurred only
intermittently within localized areas (Kuhn, 2008). The currentCell RepEbola virus disease (EVD) outbreak is substantially larger (thou-
sands rather than dozens or hundreds of cases), affecting mainly
Guinea, Liberia, and Sierra Leone. People who were infected
with EBOV in these areas have also traveled or been transported
to Mali, Nigeria, Senegal, Germany, Spain, the United Kingdom,
and the United States (WHO, 2014b). The situation in the
Western Africa outbreak area and the risk of expansion to other
countries prompted the World Health Organization to adopt
emergency measures to contain the outbreak, such as support-
ing the testing of as yet unapprovedmedical countermeasures in
the affected human population (WHO, 2014a).
At least four types of post-exposure therapeutics have been
effective in reducing mortality in NHPs after EBOV inoculation.
These include (1) small interfering RNA (siRNAs) (Geisbert
et al., 2010), (2) phosphorodiamidate morpholino oligomers
(PMOs) antisense strategies (Iversen et al., 2012; Warfield
et al., 2006; Warren et al., 2010), (3) vesicular stomatitis Indiana
virus (VSV)-based vaccines (Feldmann et al., 2007; Geisbert
et al., 2008, 2009), and (4) passive immunotherapy (Olinger
et al., 2012; Qiu et al., 2012a, 2013). One example of the latter
is the monoclonal antibody (mAb) cocktail MB-003, a cocktail
of three plant-derived monoclonal antibodies, designated
c13C6, h-13F6, and c6D8. In rhesus monkeys, a benefit of
50%–100% survival was observed when MB-003 was adminis-
tered within 24–72 hr after EBOV inoculation (Olinger et al.,
2012). A study evaluating a different combination of mAbs called
ZMAb (Public Health Agency of Canada), containing mAbs 1H3,
2G4, and 4G7, resulted in 100% survival when administered to
the animals 24 hr after EBOV exposure, and 50% protection
when administered after 48 hr (Qiu et al., 2012a). During the
ongoing EVD outbreak in Western Africa, a third formulation,
ZMAPP, containing mAbs c13C6, 2G4, and 4G7 (Qiu et al.,
2014b; WHO, 2014b), has been administered to seven EBOV-in-
fected patients. Five of them survived, but it is unclear whether
survival was linked to the treatment (McCarthy, 2014). Moreover,
due to the depletion of the stockpile of ZMAPP, previousorts 12, 2111–2120, September 29, 2015 ª2015 The Authors 2111
formulations are also being utilized for compassionate reasons
(Penty and Benoit, 2014).
The basic mechanism of action of these therapeutic cocktails
is the neutralization of viral replication through interaction of
these mAbs with the EBOV glycoprotein (GP1,2) (Bale et al.,
2012; Lee and Saphire, 2009). GP1,2 is responsible for Ebola
virion attachment to its cognate host cell-surface receptor and
subsequent fusion (Takada et al., 1997). GP1,2 is located on
the surface of the virion, is highly immunogenic, and is the
main target of neutralizing antibodies (Bale et al., 2012; Lee
et al., 2008; Olal et al., 2012; Wilson et al., 2000).
In a study that evaluated the efficacy of MB-003 as a post-
exposure therapeutic for EBOV infection, two of the treated
NHPs succumbed to infection (Olinger et al., 2012). To study
the possible mechanisms of this partial MB-003 failure, we
used a variety of genomic sequencing techniques to characterize
the Ebola virus population present in the animals and to monitor
the development of resistance to the therapy. The animal that
succumbed at the expected time of death (11 days post-inocula-
tion) for the infection did not show any significant changes
in genomic diversity. However, the animal that died outside of
the expected time (16 days post-inoculation) showed significant
genomic changes. Thederived viral genotypeswere cloned into a
plasmid transfection system and a phage display system to
confirm the epitope disruption, thus linking the variants to an
escape phenotype that appeared most likely in response to the
mAb cocktail therapeutic. The resistant virus was isolated from
the succumbed animal and characterized to demonstrate the
mutant variant was infectious, capable of replication and able
to also escape in vitro neutralization. Finally, retrospective anal-
ysis of a second independent study allowed the identification of
a similar virus genotype in another NHP that also succumbed to
infection on day 16, despite treatment with MB-003.
RESULTS
Viral Population Genomics
Viral populations from four different NHPs were characterized
from study A (Table S1). Individual 5C succumbed on day 16
post-infection after therapeutic treatment with MB-003 (Olinger
et al., 2012). Four blood samples were analyzed for this individual
(days 6, 10, 14, 16 post-inoculation). Two blood samples were
analyzed from a second MB-003-treated individual (NHP 3C,
days 6 and 10) that succumbed at the expected time of death
(11 days post-inoculation). Additionally, analysis was performed
in two mock-treated individuals, as controls (NHP 4C and 8C,
days 6 and 7 post-inoculation). Deep sequencing of the entire
viral genome was performed for each sample to characterize
the viral population and to compare with the diversity observed
in the viral stock utilized for inoculation (methods previously
described [Kugelman et al., 2012]). While the viral genomic pop-
ulations remained relatively homogeneous and unchanged in the
samples taken at days 6 and 10 for animal 5C (and in all samples
obtained from 3C, 4C, and 8C), the resulting single nucleotide
polymorphism (SNP) profile indicated the appearance of signifi-
cant subclonal diversity by day 14 that increased at day 16. Nine
changes >2% were observed, which clustered in two regions of
the GP gene (positions 6854–6885 and 7221–7256; Figure S1).2112 Cell Reports 12, 2111–2120, September 29, 2015 ª2015 The AThese regions overlap with the protein binding sites of the
mAbs: c6D8: 7204–7252, h-13F6: 7240–7288, and c13C6:
6039–7134 (Table S2) (Wilson et al., 2000). mAbs c6D8 and
h-13F6 are known to bind to linear epitopes, whereas c13C6
was found to bind to a conformational epitope in the GP1 subunit
of GP1,2 (Wilson et al., 2000). One of the SNPs (position 6854)
was an A to C transversion, the rest were A to G transitions.
These SNPs led to five nonsynonymous changes, one of which
(K272N) was in a structured region near the mucin-like domain
within the full-length GP1,2. The other nonsynonymousmutations
(T283A, D397G, Q406R, and the pleomorphic position K395R/
G/E) were located within the nearby mucin-like domain at the
virion/host-cell interface; however, structural information for
this region is not yet available.
We previously demonstrated that the ebolavirus genome
displays significant plasticity while changing in vivo and in vitro
replication states (Kugelman et al., 2012). A change in the glyco-
protein (GP) gene-derived mRNA caused by co-transcriptional
polymerase stuttering at a polyadenylyl site results in the most
significant change and relates to the ratio of 7U/8U forms (8U
is preferred in vitro, while the 7U genotype is quickly recovered
once the cell-culture passaged virus is utilized to infect an
NHP). A similar pattern was described previously in guinea
pigs (Volchkova et al., 2011). The 7U/8U ratio is important as it
will affect the proportion of full-length GP1,2 (8U) to secreted var-
iants of unknown function, sGP (7U) and rarely ssGP (6 and 9U),
during infection. While we observed this classical pattern (quick
reversion to the 7U genotype) in all control animals (4C and 8C),
and the treated animal that succumbed 11 days post-infection
(3C); the animal 5C from which we recovered the viral escape
mutant only slowly reverted to the 7U genotype (20% 7U at
day 6; 33% at day 10; 40% at day 14 and 97% at day 16).
Viral Haplotype Phasing
The two observed clusters of mutations are situated approxi-
mately 400 nt apart, which is too far for individual reads from
the Illumina dataset to span. Therefore, we utilized long reads
from the Pacific Biosciences platform to determine whether
these mutations occurred on the same or on different RNA mol-
ecules. A summary of the observed haplotypes is provided in
Table 1. A haplotype is reported if it was significantly detected
in both replicates of a particular sample (p% 0.05). As expected
from the Illumina data, only one significant haplotype was de-
tected in the samples taken from animal 5C on days 6 and 10.
Nine significant haplotypes were detected on day 14, which
are estimated to range in frequency from 1.2%–63.7%, and 11
haplotypes were detected on day 16, with frequencies estimated
to range from 1.7%–26.4%. The frequency of the wild-type (WT)
genotype decreased over time, starting with the day 14 sample,
and by day 16, only 17.5% of the population still contained the
WT genotype at the nine focal positions. We were unable to
resolve a single evolutionary trajectory due to the presence of
several loops in the haplotype network (Figure 1). Given the an-
imal was challenged with a high-dose intra-muscular inoculation
(690 pfu/ml) (Olinger et al., 2012), it is most likely that these loops
are the result of homoplasies (i.e., the same mutations occurring
in multiple different lineages); however, this pattern could also
result from recombination.uthors
Table 1. SNP Phasing
Genotype Non-Synonymous
Day 6 Day 10 Day 14 Day 16
Pop (%) ± (%) Pop (%) ± Pop (%) ± (%) Pop (%) ± (%)
1 C G G A G G A A A N A R G 13.69 1.32 26.41 4.56
2a A A A A A A A A A K T K D Q 98.71 1.29 100.00 63.73 3.14 17.47 0.16 WT
3 A A A G G A A G G G R 3.32 1.69 15.02 1.24
4 A A A A G G A A A R G 5.35 0.50 14.67 1.81
5 A A A G G A G G G G R 1.47 0.50 7.33 0.82
6 A A A A G A A A A R 1.84 0.04 2.92 0.77
7 A A A A A A A G A R 2.59 0.95
8 C G G A A A A A A N A 2.16 0.48 2.59 0.93
9 C G G G G A A G G N A G R 2.21 0.95
10 C G G A G A A A A N A R 1.22 0.12 1.76 0.32
11 A G G A G G A A A A R G 1.67 0.29
12 C A A A A A A A A N 3.52 0.71
6854 6857 6885 7221 7222 7228 7247 7255 7256 272 283 395b 397b 406b
EBOV from an animal that succumbed to infection on day 16was subjected to amplicon sequencing, spanning both sites of interest (GP gene positions
6854–7256) on the Pacific Biosciences RS, in duplicate. This table contains a listing of the haplotypes, non-synonymous changes, and the estimated
percentage of population by day for each haplotype. Only haplotypes that were significantly detected (p% 0.05, binomial distribution) in both repli-
cates are shown. Nucleotide references refer to genome positions based on reference sequence AY354458; amino acid positions refer to the position
from the start site of the GP gene-encoded GP1,2.
aThe wild-type sequence from the EBOV stock is designated (WT in the last column) for reference.
bResidues located in the mucin-like domain.Evaluation of the Effect of the Observed Changes on
Antibody Binding
To investigate the biological effect of the observed changes, we
expressed WT and modified EBOV GP1,2 containing the nonsy-
nonymous changes described in the haplotype analysis (mu-
tants D1S1 [K272N, T283A], D2S1 [K395G, D397G, Q406R],
D1-2S1 [K272N, T283A, K395G, D397G, Q406R]) in a transient
eukaryotic expression system using HeLa cells. Mutant D1 con-
tains all of the nonsynonymous changes observed within the first
cluster of mutations (6854–6885), mutant D2 contains all of the
nonsynonymous changes in the second cluster (7221–7256),
andD1-2 includes the changes from both clusters. GP1,2 expres-
sion was assessed by high-content imaging microscopy with a
rabbit polyclonal EBOV-GP1,2 antiserum (IBT Bioservices). A
panel of four conformational monoclonal antibodies (including
mAb KZ52, a ‘‘base’’ GP1,2 binding antibody [Dias et al., 2011;
Maruyama et al., 1999]), and the corresponding individual MB-
003 mAbs (c6D8, c13C6, and h-13F6) were also assessed to
address correct GP1,2 folding and possible epitope disruption,
respectively. The four mAbs that bind conformational epitopes
recognized the wild-type or mutated GP1,2 similarly, proving
that the mutations added to GP1,2 have no major effects on the
overall GP1,2 conformation and folding (Figure 2A). The quantita-
tive high-content imaging analysis confirms that the amino acid
changes introduced in the EBOV glycoprotein significantly
disrupt non-competitive binding of the three monoclonal anti-
bodies comprising MB-003 (Figure 2A). Changes to each region
were sufficient to reduce binding efficiency as compared to WT
across all mutants. Remarkably, changes introduced into the D1
region of GP1,2, outside the known linear epitope for mAbs c6D8
and h-13F6, also disrupt binding; this is likely due to conforma-
tional changes in the GP1,2 structure that do not affect the otherCell Repfour mAb antibodies tested. No localization changes for any of
the mutant versions of GP1,2 were seen in the microscopy anal-
ysis (Figure S2). The mAb c13C6 recognition site has been
described as conformational and it has been unequivocally
identified to react with sGP (Wilson et al., 2000). Intriguingly,
the findings that mutations in both regions disrupt c13C6 binding
suggests they are directly or indirectly involved in the c13C6
conformational epitope. Given the disordered nature of this re-
gion of the protein, we cannot speculate about the structural ef-
fects that might contribute to these changes in affinity. Additional
workmight be necessary to define the precise binding properties
of this mAb, which is included not only in MB-003, but also in its
successor, ZMAPP (Qiu et al., 2014b; WHO, 2014b).
Although these experiments indicate the loss of binding of the
mAbs to the virus GP1,2, and therefore suggest that the muta-
tions observed are the result of positive selection imposed by
the passive immunotherapy treatment, these experiments are
non-competitive. To test the preference of the binding of the
antibody in a mixed population, we developed a system based
on phage display, in which we expressed the different haplo-
types and used the monoclonal antibodies to competitively
select from the expressing phages within the library. Phages dis-
playing the WT sequence or peptides representing the haplo-
types of D2 (K395R/G, D397G, Q406R) were panned against
mAbs c6D8 and h-13F6. Resulting bound and unbound phage
libraries were deep sequenced to provide differential expression
data. Figure 2C depicts the enrichment or reduction of binding
affinity to each mutant phage. All of the haplotypes tested
affected the binding of h-13F6 or c6D8 to their known binding re-
gions. Monoclonal antibody h-13F6 led to an average reduction
of 94.3% ± 1.1% in enrichment compared to WT for variants
containing Q406R, whereas changes occurring further upstreamorts 12, 2111–2120, September 29, 2015 ª2015 The Authors 2113
Figure 1. Haplotype Network
A haplotype network depicting the 12 EBOV
haplotypes detected in the blood samples from
individual 5C. Each line corresponds to a single
genetic change. The colored circles represent
detected haplotypes, and the white circles repre-
sent inferred haplotypes that were not detected.
The size of each circle is relative to the estimated
frequency of the haplotype on day 16 (except for
the blue haplotype, which was only detected on
day 14). The wild-type haplotype is shown in gray;
the other haplotypes are colored based on their
detected ability to disrupt the binding of the three
therapeutic monoclonal antibodies (Figure 3).of the published binding site led either to no change in
abundance or modest, highly variable reductions (on average
18.2% ± 23.9% enrichment compared to WT). This result is
expected since the mutation at Q406 is a key contact of 13F6
(Lee et al., 2008). Monoclonal antibody c6D8 led to a reduction
of 97.3% ± 0.3% enrichment as compared to WT across muta-
tions in the published binding region (Wilson et al., 2000),
whereas the single Q406R mutation that lies downstream led
to a 65.7% ± 10.4% reduction in enrichment compared to WT.
Recovery of Mutant Virus
In the original study evaluating MB-003, EBOV was not recov-
ered from the samples collected from animal 5C on day 16 (Olin-
ger et al., 2012). We repeated that isolation attempt with the goal
of ensuring that the mutated virus was viable. We observed a
cytopathic effect after two blind passages and 14 days of culture
in Vero E6 cells (7 days per passage). EBOV was harvested and
subjected to deep sequencing analysis. Table 2 summarizes the
sequencing results covering the area of interest. The recovered
EBOV population carried all five nonsynonymous mutations.
The predominant haplotype (79% frequency) matched the
most abundant haplotype present at day 16 (haplotype 1 in
Table 1). Only one additional nonsynonymous change was ac-
quired during passaging (R409C), which indicated that these
mutations do not dramatically impact fitness in vitro. Neither
the pool of themAbs that formed the cocktail nor two of the three
individual mAbs neutralized the virus recovered from NHP 5C at2114 Cell Reports 12, 2111–2120, September 29, 2015 ª2015 The Authorsday 16 or a plaque purified virus from the
same stock (Figure 3). The same pool and
each individual mAb (c13C6 or c6D8)
reduced 80% of the wild-type EBOV
stock plaques at a concentration of 12.5
or 25 mg/ml, respectively. Monoclonal
antibody h-13F6 was not tested individu-
ally as it does not have in vitro neutralizing
properties (Wilson et al., 2000).
Retrospective Evaluation of
Treatment Failures
We were able to retrospectively identify
two additional individuals that were also
unsuccessfully treated with MB-003.
One treated individual succumbed at day 11 p.i. (NHP10); the
second succumbed at day 16 (NHP01). A mock-treated animal
that succumbed on day 10 p.i. from the same study was also
analyzed as a control (NHP04). All three NHPs were assayed
for diversity in the region identified above (6800–7300 nt) using
high-throughput amplicon sequencing. No significant sub-clonal
diversity was detected in this region in NHP10 or NHP04. How-
ever, NHP01 (which succumbed later at day 16 p.i.) presented
two sub-clonal clusters of diversity in this region by day 14
(Table 3). These clusters overlap with the clusters observed in
animal 5C. In fact, four of the variant amino acid positions
observed in animal 5C were also variable in NHP01 (though the
exact same mutation was not observed in all cases, and one
of the mutations [7255] was observed at a lower level). Two
additional high-frequency sub-clonal nonsynonymous variant
positions (6849 and 7263) were also identified. We introduced
these mutations into GP1,2 as described before (mutants D1S2
[G271R, K272I], D2S2 [K395E, D397G, Q406L, R409C], D1-
2S2 [G271R, K272I, K395E, D397G, Q406L, R409C]). A quantita-
tive high-content imaging analysis using this additional set of
haplotypes confirms that the changes introduced in the EBOV
glycoprotein significantly disrupt binding of MB-003 without
affecting conformational antibody bindings or localization of
GP1,2 (Figures 2B and S3). Moreover, changes introduced into
the D1 region of GP1,2 disrupt binding of mAbs c6D8 and
h-13F6, while changes introduced into the D2 region disrupt
c13C6, confirming the results observed with animal 5C.
Figure 2. Binding Defect Analysis
High content imagingwas performed on average >5,000 cells across 56 fields in quadruplicate experiments. Immunostaining average intensities are displayed for
each mAb in the MB-003 cocktail, a polyclonal antibody as control and four conformational monoclonal antibodies as controls of proper folding. Error bars
represent SD. Statistically significant (p% 0.05, Student’s test) variation from WT is denoted by an asterisk. For full imagery set, see Figures S2 and S3. (A) 5C
mutants. (B) NHP01 mutants. (C) Viral variant phage-capture competition. Oligonucleotides containing the sequence of the viral variants spanning the D2 site
were synthesized and cloned into phages. The phages express the corresponding peptides and were enriched using the therapeutic mAbs c6D8 and h-13F6, in
duplicate. Binding activities of the variant haplotypes were normalized against the wild-type for each antibody in duplicate experiments.DISCUSSION
Our ability to follow the classical paths of research in the study
of antiviral resistance mechanisms is severely impaired when
therapeutics target select agents, such as EBOV. This is due to
restrictions resulting from the policies regarding gain-of-function
experiments and dual-use concerns that limit the ability to pur-
posefully generate variants that escape medical countermea-
sures. Limitations related with gain-of-function experiments
precluded us to perform in vivo studies with the viral escape
mutant strain that could have measured its potential in vivo
fitness. Thus, a thorough analysis of all treatment failures during
experimentation in surrogate animal models becomes crucial to
identify pathways of resistance. Due to the limited number of in-
dividuals who are tested in such studies owing to financial, logis-
tic, and ethical concerns, the results can rarely be generalized.
It is therefore highly desirable to perform viral population
genomics studies and to monitor the appearance of mutants
that might confer resistance to candidate therapeutics. Fortu-
nately, currently existing capabilities for high-throughput, deep
genomic sequencing facilitate this task.
The set of resistance-conferring mutations reported here ap-
peared during the course of an EBOV infection in a rhesus mon-
key over 16 days and appear to be sufficient to overcome the
protective capability of three promising mAbs that protected
other individuals in the same study. These mutations were not
observed in any other EBOV-RNA positive animal from the
same study. The resulting EBOV variant appeared to be fit,
although it was necessary to perform blind passages to recoverCell Repit. The recovered viral population does not show any fitness
costs in vitro, as demonstrated by normal growth curve and pla-
que size. The observed changes were not lost during further pas-
sage of the population, i.e., they seem to be genetically stable.
The isolated virus was not neutralized in vitro by either of the
two neutralizing mAbs (c6D8 and c13C6) or the cocktail, demon-
strating conclusively that the virus was an escape mutant.
Strikingly, a very similar resistant genotype arose indepen-
dently in a second NHP that succumbed at day 16 in a different
study that included similar treatment and inoculation parame-
ters. To date, 41 NHPs have been treated with MB-003 in six in-
dependent NHP animal experiments performed with the goals of
evaluating proper dosage, antibody composition, and effective
window of treatment. Seventeen (41.5% of total) succumbed
despite treatment, two of which (11.8% of the deceased; 4.8%
of total) succumbed on day 16, a time that is considered outside
the normal time of death for the EVD NHP model. The virus pop-
ulations in both of these cases developed similar mutations.
While our studied sample number does not support statistical
analysis among the treated individuals (n = 4), the resistancemu-
tations only occurred in the two late time-to-death animals out of
a total of seven non-survivors surveyed across two independent
studies. The other five individuals all succumbed in the normal
time-of-death windows (note: we only studied two of those ani-
mals, which exhibited a wild-type genotype at the time of death),
linking time to death with the resistance mutations (p = 0.0467;
Fisher’s exact test). Given that resistance is not detected in all
cases of treatment failure, additional unidentified factors remain
that result in loss of efficacy. These causes of failure may includeorts 12, 2111–2120, September 29, 2015 ª2015 The Authors 2115
Table 2. Population Genetics for the Recovered Virus from Animal 5C
Reference Position Base SNP Frequency (%) Codon Feature R4368a (%)
6854 A c 92.2 K:AAA @ 272/ N:AAc GP 0.05
6857 A g 91.9 L:CTA @ 273/ L:CTg GP ND
6885 A g 89.4 T:ACA @ 283/ A:gCA GP 0.20
7222 A g 99.7 K:AAA @ 395/ R:AgA GP 0.27
7228 A g 86.1 D:GAC @ 397/ G:GgC GP 0.19
7255 A g 48.3 Q:CAA @ 406/ R:CgA GP 0.06
ND, not detected.
aSequencing was also performed on the seed stock used to inoculate the NHPs for comparison, designated here as ‘‘R4368’’. None of the positions
exceeded background error (±2% of population) though the potential exists that true variants exist below this threshold.such issues as co-morbidity, genetic disorders, physical traits,
or some as-yet-unknown factor. However, no co-morbidities
were detected during physical health assessments prior to infec-
tion and/or treatment, as well as, continuous monitoring of
symptoms.
None of the mutations reported here have been identified pre-
viously in other natural EBOV isolates. Even though Ebola virus
genomic sequences are remarkably conserved over time, sug-
gesting intra-host purifying selection (Carroll et al., 2013; Suzuki
and Gojobori, 1997), filoviruses mutate with roughly the same
frequency as most other mononegaviruses. For instance, the
number of nucleotide differences between an EBOV isolate of
the current, 2014, outbreak in Guinea (KJ660346), Ebola virus/
H.sapiens-tc/COD/1976/Yambuku-Mayinga (NC_002549) iso-
lated 40 years ago, and Ebola virus Ebola virus/H.sapiens-tc/
COD/1995/Kikwit-9510621 (AY354458) isolated 20 years ago,
are 586 and 537 out of roughly 19,000 nucleotides (3%),
respectively. In that context, the speed at which EBOV popula-
tions can change when faced with strong selective pressures,
as presented here, is remarkable. This result highlights the
extreme care that needs to be maintained in the administration
of virion-targeted therapeutics for dangerous pathogens under
emergency use limitations. Our observations emphasize the
need to control the conditions during which viral targeted
therapeutics are administered to protect the efficacy of the treat-
ments. Isolation must be maintained to ensure that if viral vari-
ants are generated during treatment they are limited and end
with the current infection.
Our data indicate that theMB-003 cocktail may not be ideal for
treatment of human EBOV infections as the targets of the individ-
ual antibody components are too closely related. Two amino
acid mutations (K395G and Q406R) were enough to disrupt the
binding of the three monoclonal antibodies present in MB-003.
The formulation has since been changed by including mAbs
from the ZMAb cocktail that target different areas of EBOV
GP1,2, thus theoretically diminishing the likelihood of viral escape
(Qiu et al., 2011, 2012b). Indeed, ZMapp has now been given to
24 NHPs with treatment initiation from 3 to 5 days post-infection,
and no escape mutants have been observed to date (Qiu et al.,
2014a; WHO, 2014a). Nevertheless, given the shortage of
ZMapp antibody cocktail that resulted in the utilization in humans
of earlier formulations, it is recommended that all cases that
receive this type of treatment are closely monitored to detect
the appearance of escape variants. Despite the fact that the2116 Cell Reports 12, 2111–2120, September 29, 2015 ª2015 The Acocktail approach is attempting to mimic the multidrug (e.g.,
in comparison with monotherapy treatment) paradigm of drug
therapy that was very successful for HIV treatment, our results
appear to indicate that a head-to-head comparison to compare
rates of resistance generation between small molecules and
antibody cocktails might be warranted. Moreover, the unex-
pected observation that mutations outside the mapped epitopes
of some of these antibodies would nonetheless abrogate anti-
body binding is significant. It cannot then be assumed that a
mutation distal from the footprint of the antibody would not affect
the antibody therapeutic. Efficacy of antibody based therapeu-
tics would need to be experimentally verified with each permuta-
tion of a naturally evolving virus.
Our findings highlight several concepts that are critical to
EBOV-targeted therapeutic development: (1) viral mutation un-
der selection pressure can occur extremely rapidly (as compared
to the observed acquisition of mutations over several decades of
evolution of EBOV would suggest); (2) studies to elucidate the
most common mutations that confer phenotypic resistance are
of high priority; (3) methods for clinically monitoring the appear-
ance of resistant variants need to be established; (4) for passive
immunotherapy treatments, reformulation may be required to
overcome very rare events; and (5) vaccines, which instead
induce a polyclonal response, will surely avoid the generation
of resistance more effectively than sequence-based therapeu-
tics; (6) techniques for exploring the EBOV and host immuno-
genic fitness landscape without violating dual-use and gain-of-
function restrictions are urgently needed.
EXPERIMENTAL PROCEDURES
Post-Exposure Studies
The study design, specific reagent development, and exposure material were
reported previously (Olinger et al., 2012). In brief, the exposure stock of Ebola
virus (EBOV) H.sapiens-tc/COD/1995/Kikwit-9510621 (Filoviridae: Ebolavirus:
Zaire ebolavirus; GenBank AY354458) was prepared at the US Army Medical
Research Institute of Infectious Diseases (USAMRIID) from virus originally iso-
lated from an infected patient during the 1995 EVD outbreak in Kikwit, Zaire.
The mAbs (c13C6, h-13F6, and c6D8) that comprise MB-003 were produced
via transient expression in the plant system DXTFT Nicotina benthamiana and
mixed in equal amounts for treatment (16.7 mg/kg/mAb). Verification of target
doseand viremiawasconductedwith anagarose-basedplaque assay. Rhesus
monkeys (Macaca mulatta) were inoculated intramuscularly with a target dose
of 1,000 pfu/ml and then treated 24 hr (n = 3) or 48 hr post-infection (p.i.) (n = 3)
following the schedule at day 1, 5, 8, and 10 (24 hr) or 2, 6, 8, and 10 (48 hr). The
actual dose determined by plaque titration was 690 pfu/ml. The mAb controluthors
Figure 3. Neutralizing Antibody Assays
Viral plaques observed after 7 days p.i. in the presence 2-fold dilutions of the individual mAbs (A and B) and the MB-003 cocktail (C) were quantified for the seed
stock used to inoculate the NHPs, the passage 2 of the 5C day 16 sera, and a plaque pick virus isolated from the passage 2. No differences in the growth curve
shape or in the resulting plaque size were observed among the three viruses tested.(n = 1; irrelevant target) was paired with the 24-hr group, and the PBS control
(n = 1) was paired with the 48-hr group. For this study, blood samples were
taken on days 2, 6, 10, 14, and 16 from a rhesus monkey that succumbed to
EBOV infection on day 16 despite treatment 48 hr p.i. Blood samples were
also taken from two control animals on days 6 and 7. For each sample,
0.25 ml blood were mixed with 0.75 ml TRIzol LS (Invitrogen) for serum virus
inactivation. RNeasy kits (QIAGEN) were used for RNA extraction.
The second unpublished study (G.G.O. and J.M.D., unpublished data) fol-
lowed similar exposure methods (Olinger et al., 2012). EBOV was also admin-
istered intramuscularly, and the NHPs were treated with MB-003 (or PBS as
control) at 16.7 mg/kg/mAb at 24 hr p.i. Blood samples obtained on days 6,
9, or 10, and day 14 and 16 (for the late time-of-death NHPs) were available
for analysis.
Virus Isolation from Plasma of NHP 5C, Day 16 Post-Infection with
EBOV
EBOV was not recovered by the standard plaque assay method used for the
isolation of EBOV. Serial passages in Vero cell monolayers were needed to
isolate the virus. Briefly, a T25 with a Vero E6 confluent monolayer was inocu-
lated with 200 ml of plasma from NHP057, day 16. After adsorption for 1 hr at
37C, 5%CO2, 80%H, 5ml of growth media (EMEM [13] with L glutamine and
1% NEAA, plus 5% heat inactivated FBS) was added to the monolayer. One
T25 infected with 200 ml of EBOV and one T25 uninfected monolayer were
used as controls. All monolayers were incubated at 37C, 5% CO2, and
80% H for 7 days and were daily observed for cytopathic effect (CPE). At
day 7, 200 ml of supernatants from each T25 was transferred to fresh Vero
E6 monolayers, and the monolayers were observed for another 7 days.
Virus Titration and Plaque Picking
The titer of 5C plasma day 16, Vero P2 was determined by the standard plaque
assay method for filovirus (13 106 pfu/ml); 21 plaques were picked and ampli-
fied in Vero cell monolayers.
Animal Use Statement
Research was conducted under a protocol approved by an Institutional Animal
Care and Use Committee (IACUC) in compliance with the Animal Welfare Act,Cell RepPHS Policy, and other US federal statutes and regulations relating to animals
and experiments involving animals. The facility in which this research was con-
ducted (USAMRIID) is accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, International (AAALAC) and adheres
to principles stated in theGuide for theCare andUseof Laboratory Animals, Na-
tional Research Council, 2011. The USAMRIID IACUC approved these studies.
Rhesus monkeys were individually housed in stainless steel cages and were
provided food andwater ad libitum. Animal roomsweremaintained on a 12-hr-
light/dark cycle and equipped with toy and fruit environmental enrichments.
Animals were monitored at least twice daily for signs of distress. Buprenor-
phine was administered to animals having clinical signs of discomfort,
and meloxicam was administered to animals with elevated body temperature.
Euthanasia was performed to minimize pain and distress by intravenous
administration of sodium pentobarbital.
Dual-Use Statement
Research was conducted under an IACUC-approved protocol in compliance
with the Animal Welfare Act, Public Health Service Policy and other federal
statutes and regulations relating to animals and experiments involving animals.
The facility where this research was conducted is accredited by the Associa-
tion for Assessment and Accreditation of Laboratory Animal Care International
and adheres to principles stated in the 8th Edition of the Guide for the Care and
Use of Laboratory Animals, National Research Council, 2011.
Research has been reviewed for compliance with dual-use guidelines and
approved for publication by the USAMRIID Institute Biosafety Committee
(IBC) and the Operational Security office.
Sequencing
Population Genomics Studies
cDNA synthesis was performed using Invitrogen’s Superscript III First-Strand
Synthesis System. cDNA was amplified with Phusion Hot Start Flex DNA
Polymerase (New England Biolabs) using overlapping 1,500-kb amplicons
(primer information available upon request). After pooling and purification
with AMPure XP Reagent (Beckman Coulter), PCR products were fragmentedorts 12, 2111–2120, September 29, 2015 ª2015 The Authors 2117
Table 3. Population Genetics for the Recovered Virus from
Animal NHP01
Reference
Position Base SNP
Frequency
(%) Codon Feature
6849 G C 21.85 G:GGA @ 271/ R:aGA GP
6853 A T 49.14 K:AAA @ 272/ I:AtA GP
6885 A g ND T:ACA @ 283/ A:gCA GP
7221 A g 2.20 K:AAA @ 395/ E:gAA GP
7228 A g 17.53 D:GAC @ 397/ G:GgC GP
7255 A g 0.49 Q:CAA @ 406/ L:CtA GP
7263 C t 40.90 R:CGC @ 409/ C:tGC GP
ND, not detected.using the Covaris S2 instrument (Covaris). Libraries were prepared with the
Illumina TruSeq DNA Sample Preparation kit (Illumina) on the Caliper
ScicloneG3 Liquid Handling Station (PerkinElmer). After measurement by
real-time PCR with the KAPA qPCR Kit (Kapa Biosystems), libraries were
diluted to 10 nM. Cluster amplification was performed on the Illumina cBot,
and libraries were sequenced on the Illumina HiSeq 2500 using the 76 bp
paired-end format (Kugelman et al., 2012).
Haplotype Sequencing Studies
cDNA was used as a template to generate a 1,500-bp amplicon spanning the
EBOV GP gene positions 6490–7933 using touchdown PCR. Amplicons were
purified using QIAGEN MinElute columns, and amplicon quality and concen-
tration was measured with the Agilent 2100 Bioanalyzer. For sequencing on
the PacBio RS II instrument, 2-kb libraries were generated and processed
using the SMRTbell Template Prep Kit 1.0, the DNA/Polymerase Binding
Kit P4, and the DNA Sequencing Reagent 2.0 (Pacific Biosciences). Two repli-
cate amplicons were generated for each sample, and each replicate was
sequenced on two SMRT cells.
Phage Sequencing
Phages recovered in the unbound and bound fraction were amplified by PCR
using specific primers flanking the cloned oligos on the T7 phages. PCR ampli-
fication was performed with a denaturing step of 94C for 3 min, 32 cycles of
94C for 20 s (denature)/60C for 20 s (annealing)/72C for 30 s (extension),
and a final extension step of 72C for 10 min. Amplicons were recovered,
cleaned using the QIAquick PCR purification kit (QIAGEN) and prepared for
sequencing on the Illumina MiSeq. Sequencing libraries were run utilizing a
500 cycle kit (2 3 250 bp).
Analysis
Population Genomics Alignments
Viral assemblies were completed in DNAStar Lasergene nGen. Amplification
primer removal, quality trimming, and trim-to-mer were performed on reads
with a minimum similarity to the reference of 93% (four-base mismatch).
SNPs at positions with fewer than 200 read depth were removed from the anal-
ysis. A consensus change is defined here as a change relative to the deposited
EBOV sequence (GenBank AY354458) present in R50% of the population.
Below that threshold, SNPs were considered sub-clonal substitutions and
part of a minority subpopulation of the virus. Only SNPs present in the popu-
lation above the 2% threshold are presented in this report.
Haplotype Analysis
Custom scripts were used to identify multilocus haplotypes using the PacBio
sequences. To reduce error rates, circular consensus sequences (CCSs) were
used with a minimum quality cutoff of 90 and a minimum number of full passes
of 2. BLASR v.1.3.1 (Chaisson and Tesler, 2012) was used to align the CCS
reads to the EBOV reference with N’s substituted for the reference bases at
the nine positions of interest (to minimize alignment bias; Carneiro et al.,
2012). Reads were only utilized to infer haplotypes if a non-gapped alignment
was achieved at all nine bases of interest. The binomial distribution was used
to calculate the significance of each haplotype (i.e., likelihood that the haplo-
type was seen more often than would be expected by chance). The utilized2118 Cell Reports 12, 2111–2120, September 29, 2015 ª2015 The Aerror rate, 0.005, was calculated based on 100 simulated datasets (PBSIM
with default parameters; Ono et al., 2013), which each included nine randomly
selected variable sites, one primary haplotype (95% frequency), and fiveminor
haplotypes (1% each). This error rate resulted in a precision of 0.998 (only one
false-positive haplotype in all 100 simulations) and a recall of 1. Through
repeated simulations it is clear that false-positives (FPs) are most likely to
occur when one haplotype dominates the population (FPs are typically one
base different from the dominant haplotype); therefore, the error rate chosen
from these simulations is expected to be conservative for many real datasets.
For each sample, the Bonferroni correction was used to control for multiple
tests (# tests = # of detected haplotypes). A haplotype network was created
using HapStar (Excoffier and Lischer, 2010; Teacher and Griffiths, 2011) to
visual the relationships among the detected haplotypes.
Mutagenesis and Transient Expression
Transient Transfection
For transfection, HeLa cells were used at a confluence of 60%–80% plated in
96-well plates (Greiner Bio-one catalog no. 655090). cDNA from the respective
constructs (plasmids expressing EBOV wild-type GP1,2 [wtGP]) and mutants
D1S1 (K272N, T283A), D2S1 (K395G, D397G, Q406R), or D1-2S1 (K272N,
T283A, K395G, D397G, Q406R) (set 1) and D1S2 (G271R, K272I, T283A),
D2S2 (K395G, D397G, Q406R, R409C), or D1-2S2 (G271R, K272I, T283A,
K395G, D397G, Q406R, R409C) (set 2; underlined, additional mutation posi-
tion; in italic, type of amino acid change) were prepared in serum-free
DMEM. A mixture of 1 ml Lipofectamine 2000 in 24 ml serum-free DMEM and
25 ml of diluted plasmid (for a final volume of 50 ml, 300 ng of cDNA) per sample
was incubated at room temperature for 20min and then added to the cells and
incubated for 6 hr at 37C. Transfected cells were later washed with mainte-
nance media (DMEM with 10% FBS) and incubated for 24 hr to allow GP1,2
expression. Cells were washed with PBS and lysed with Pierce IP Lysis buffer.
High Content Imaging
Transfected cells were fixed with ice-cold methanol (20C) for 15 min at 4C
and permeabilized using 0.1% Triton-x 100 (Sigma-Aldrich, X-1005ML) for
10 min at room temperature. The cells were then washed twice with PBS
and blocked with a solution containing 3% BSA (Fraction V) in PBS for 1 hr
at room temperature. EBOV GP1,2 was detected using the mouse monoclonal
antibodies c6D8, c13C6, or h-13F6, human monoclonal antibody KZ52,
mouse conformational monoclonal antibodies 3H8, 14B3, and 8C10, and the
rabbit polyclonal antibody (IBT Bioservices, 0301-015) at a concentration of
1 mg/ml. Primary antibodies were diluted in 3% BSA and 100 ml added to
each well for 1 hr. The cells were then washed three times with 0.1% PBS-T.
The secondary antibody was added to each well at a concentration of
500 ng/ml (Alexa Fluor 488 for mouse monoclonal antibodies, Alexa Fluor
488 for human monoclonal antibody, and Alexa Fluor 555 for rabbit polyclonal
antibody), incubated for 1 hr in the dark, and then the cells were washed three
times with 0.1% PBS-T. The cell nuclei were stained with 1 ng/ml of Hoechst
33342 stain, and the plasma membranes were stained with 5 ng/ml of Cell
Mask Deep Red. High content data were acquired and analyzed on the
Operetta (PerkinElmer) high-throughput, wide-field fluorescence microscope
reader (PerkinElmer) using the non-confocal setting with a 203 objective.
On the operetta, images in the Blue (Hoechst 33342), Green (GFP or Alexa
488), DsRed (RFP 554), and Far Red (Cell Mask Deep Red) channels were
sequentially acquired by a single charged-coupled device (CCD) camera.
For each field of acquisition (63 fields were analyzed per well), a single imaging
plane was automatically set by using an infrared laser based autofocus unit.
The excitation light was provided using a 300 W Xenon lamp and images
were acquired using a 203 long working distance objective. Image analysis
was performed using the Harmony 3.0 software package (PerkinElmer).
Phage Display Competition
Oligonucleotides, encoding 28-mer peptides (WT: ‘‘THNTPVYKLDISEATQVE
QHHRRTDNDS’’), were designed to express epitopes from either wild-type
GP1,2 or the mutations observed in the viral population genetics study. Oligo-
nucleotides were commercially printed (Eurofins Genomics) and cloned into
the phage display plasmid (T7Select, EMD-Millipore) following the manufac-
turer’s protocols. Monoclonal antibodies were coated at 10 mg/ml on 24-well
plates in triplicates and incubated for 16 hr at 4C. mAb dilutions were washed
with 0.1 N NaHCO3 buffer (pH 8.6), and plate wells were blocked with 500 mluthors
10% BSA solution for 2 hr at 22C. Blocking solution was removed from wells
and plates were washed twice. 400 ml of the phage library was added per
well,and plates were incubated 16 hr at 4C. The unbound phage fraction
was collected from the well and stored at 4C. Plates were washed four times
with TBS + 0.05% Tween 20. In the last two washed, plates were incubated for
20 min at 22C before removal of the washing buffer. Bound phage fraction
was collected from the wells after the fourth wash. Both fractions were stored
at 20C until sequencing.
Paired end reads produced on the Illumina MiSeq 2 3 250-bp kit were pro-
duced for the analysis. The reads were aligned read 1 to read 2 using the local
aligner BLAST software from NCBI. The alignments were then used to correct
sequencing errors. SNPs occurring only in one read were removed based on
proximity to the 50 end. Base calls near the 50 end of the read were maintained.
N’s were discarded and the base from the opposing read was used. Tags used
in the cloning process were used to determine the limits of the insert and the
tags, and any Illumina adaptor sequences were trimmed. Reads that failed
to be covered by both reads across the entire insert were removed as
sequencing errors. The corrected reads were then compared to the original
library design for categorization.
Neutralizing Antibody Assays
Two-fold dilutions of c13C6, c6D8, and h-13F6 or an equal combination of
the three ranging from 3.12 mg/ml to 100 mg/ml were first incubated with
80 p.f.u. of EBOV at 37C for 1 hr with or without complement, transferred to
Vero E6 cells, and incubated at 37C for 1 hr. After adsorption, monolayers
were overlaid with a 1:1 mixture of EBME, 10% FBS, 1% penicillin strepto-
mycin (10,000 U/ml), and 1% agarose. Plates were incubated for 7 days at
37C, 5%CO2, 80% humidity. A second overlay of 1:1 EBME and 1% agarose
plus 5% neutral red was added, and plaques were counted 24–48 hr later.
Titers were calculated when observing an 80% plaque reduction compared
with the test control. Wild-type virus, the passage 2 of a virus recovered
from the 5C animal at day 16, and a subsequently obtained plaque purified
virus were used for neutralization experiments.
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